Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer
NCT ID: NCT06009510
Last Updated: 2023-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
500 participants
OBSERVATIONAL
2024-09-30
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future bladder cancer patients and play an active role in advancing medical research.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bladder Cancer Patient-Reported Outcomes
NCT01090388
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
NCT07225127
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
NCT05672615
The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease
NCT00829920
Markers of Response to Intravesical Bladder Cancer Therapy
NCT01007058
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has been diagnosed with bladder cancer
* Patient is a minimum of 18 years or older
Exclusion Criteria
* Inability to perform regular electronic reporting
* Patient is pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Power Life Sciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael B Gill
Role: STUDY_DIRECTOR
Power Life Sciences Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Power Life Sciences
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions. Urol Oncol. 2021 Jan;39(1):41-51. doi: 10.1016/j.urolonc.2020.08.016. Epub 2020 Sep 9.
Gaya JM, Territo A, Woldu S, Schwartzmann I, Verri P, Gonzalez-Perez L, Cozar JM, Minana B, Medina RA, de la Rosa-Kehrmann F, Lozano-Palacio F, Ribal MJ, Hernandez C, Castineiras JJ, Requena MJ, Moreno J, Caraballido JA, Baena V, Breda A, Palou Redorta J. Incidental diagnosis of bladder cancer in a national observational study in spain. Actas Urol Esp (Engl Ed). 2023 Jun;47(5):296-302. doi: 10.1016/j.acuroe.2022.09.005. Epub 2022 Oct 1. English, Spanish.
Malhotra B, Hiteshi P, Khalkho P, Malik R, Bhadada SK, Bhansali A, Shafiq N, Malhotra S, Kumar N, Rajput R, Rastogi A. Bladder cancer with pioglitazone: A case-control study. Diabetes Metab Syndr. 2022 Nov;16(11):102637. doi: 10.1016/j.dsx.2022.102637. Epub 2022 Oct 8.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
87986229
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.